Report from "International Workshop for Junior Fellows 2: Tocolytic treatment for prevention of preterm birth" at the 73rd Annual Congress of the Japan Society of Obstetrics and Gynecology.
Atosiban
Japan
Korea
Taiwan
magnesium sulfate
nifedipine
preterm birth
ritodrine hydrochloride
tocolytic treatment
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
08
06
2021
accepted:
20
07
2021
pubmed:
20
8
2021
medline:
4
11
2021
entrez:
19
8
2021
Statut:
ppublish
Résumé
At the 73rd Annual Congress of the Japan Society of Obstetrics and Gynecology, we discussed recent tocolytic treatments for the prevention of preterm birth with obstetricians from Korea and Taiwan. The rate of preterm birth in our countries has been increasing, and optimal tocolytic treatments are of great concern. Ritodrine hydrochloride was the first available drug for tocolysis in our countries and is often administered for over 48 h, although it is not recommended for maintenance therapy in Western countries. Meanwhile, there are differences in the use of other tocolytic drugs, based on approval of the drugs and the health insurance systems. Nifedipine and atosiban have not been considered first-line agents in Japan. The long-term use of unnecessary tocolysis should be avoided, and the introduction of other tocolytic drugs, including nifedipine or atosiban, should be discussed.
Substances chimiques
Tocolytic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3758-3760Informations de copyright
© 2021 Japan Society of Obstetrics and Gynecology.
Références
Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379:2162-72.
Sakata S, Konishi S, Ng CFS, Watanabe C. Preterm birth rates in Japan from 1979 to 2014: analysis of national vital statistics. J Obstet Gynaecol Res. 2018;44:390-6.
Nakamura M, Hasegawa J, Arakaki T, Hamada S, Takita H, Oba T, et al. Comparison of perinatal outcomes between long-term and short-term use of tocolytic agent: a historical cohort study in a single perinatal hospital. J Obstet Gynaecol Res. 2016;42:1680-5.
Takagi K, Satoh T. Is long-term tocolysis effective for threatened premature labour? J Int Med Res. 2009;37:227-39.
Shigemi D, Aso S, Yasunaga H. Inappropriate use fo ritodrine hydrochloride for threatened preterm birth in Japan: a retrospective cohort study using a national inpatient database. BMC Pregnancy Childbirth. 2019;19:204.
Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev. 2014;6:CD004452.
Chang YK, Tseng YT, Chen KT. The epidemiologic characteristics and associated risk factors of preterm birth from 2004 to 2013 in Taiwan. BMC Pregnancy Childbirth. 2020;20:201.
Hoh JK, Lappas M, Liu C, Qiao C, Pallavi K, Takeda J, et al. Preterm birth rate and dilemma of preterm labor treatment in Asia. Placenta. 2019;79:68-71.
Yu Y, Yang Z, Wu L, Zhu Y, Guo F. Effectiveness and safety of atosiban versus conventional treatment in the management of preterm labor. Taiwan J Obstet Gynecol. 2020;59:682-5.
US Food and Drug Administration. FDA Drug Safety Communication: New warnings against use of terbutaline to treat preterm labor. 2011 [cited 2021 May 31]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm243539.htm
European Medicines Agency. Restrictions on use of short-acting beta-agonists in obstetric indications-CMDh endorses PRAC recommendations. 2013 [cited 2021 May 31]. Available from: https://www.ema.europa.eu/news/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. Practice bulletin no. 171: Management of Preterm Labor. Obstet Gynecol. 2016;128:e155-64.
van Vliet EOG, Nijman TAJ, Schuit E, Heida KY, Opmeer BC, Kok M, et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016;387:2117-24.
Murata T, Kyozuka H, Yasuda S, et al. (2021) Effects of acute tocolysis using ritodrine hydrochloride on foetal heart rate patterns in intrauterine foetal resuscitation: a retrospective, single-centre observational study, J Obstet Gynaecol, https://doi.org/10.1080/01443615.2021.1929111
Murata T, Kyozuka H, Yasuda S, et al. Association between maternal ritodrine hydrochloride administration during pregnancy and childhood wheezing up to three years of age: the Japan environment and Children's study. Pediatr Allergy Immunol. 2021. https://doi.org/10.1111/pai.13545 Epub ahead of print.